Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 1157

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 13
Chunk 1157
---
 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    32.2§
     
    Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    97.1
     
    Conduit Pharmaceuticals, Inc. Compensation Recovery Policy (filed as Exhibit 97.1 to the Registrant’s Annual Report filed on April 16, 2024, and incorporated herein by reference).

    101.INS*
     
    Inline
    XBRL Instance Document.

    101.CAL*
     
    Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.

    101.SCH*
     
    Inline
    XBRL Taxonomy Extension Schema Document.

    101.DEF*
     
    Inline
    XBRL Taxonomy Extension Definition Linkbase Document.

    101.LAB*
     
    Inline
    XBRL Taxonomy Extension Labels Linkbase Document.

    101.PRE*
     
    Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.

    104
     
    Cover
    Page Interactive Data File (embedded within the Inline XBRL document).

*
Filed herewith.

#
Management contract or compensatory plan or arrangement.

+
Certain portions of this Exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish
supplementally an unredacted copy of this Exhibit to the SEC upon its request.

§
In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Management’s Reports
on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished
in Exhibits 32.1 and 32.2 hereto is deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for
purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under
the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

Item
16. Form 10–K Summary

None.

92

SIGNATURES

P